Tag Archives: drug

UPDATE 2-Pfizer to buy cancer drug developer Trillium in $2.3 bln deal

(Adds details on Trillium’s drug candidates, share movement) Aug 23 (Reuters) – Pfizer Inc said on Monday it would buy Canadian drug developer Trillium Therapeutics Inc in a $2.26 billion deal to strengthen its arsenal of blood cancer therapies. Pfizer, which acquired a $25 million stake in Trillium last year, will buy the remaining outstanding shares for $18.50 apiece, representing a 203.8% premium on the stock’s last closing price. Pfizer expects to benefit from Canada-based Trillium’s… Source link

Read More »

Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder

NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) informed the Company in a teleconference on August 20, 2021, that its review of the new drug application (NDA) for AXS-05 for the treatment of major depressive disorder would not be completed by the Prescription Drug User Fee… Source link

Read More »

Labor shortage accelerates shift away from drug testing for new hires

Drug tests are no longer required for most jobs in the municipal offices for Isle, Minnesota, a small town tucked on the southeastern corner of the Mille Lacs Lake. The reason? The town’s liquor store needs just one more person so that its owner, Don Graber, can stop working double shifts on the weekend. “There’s a lot of things that are scaring away potential hires and that was one of them,” Graber told Yahoo Finance. Graber successfully lobbied the town to eliminate the drug test, a… Source link

Read More »

Fate of Biogen’s Stock Rides on Alzheimer’s Drug Decision

(Bloomberg) — For Biogen Inc., the Food and Drug Administration’s expected decision Monday on its Alzheimer’s drug is what a JPMorgan Chase & Co. analyst called “the mother of all binary events” — one that could send its shares veering sharply in either direction. If regulators give the company approval to market the drug, called aducanumab, the stock could surge to as much to $450, according to Wall Street analysts. Or it could tumble to $200 if the treatment is shot down,… Source link

Read More »

Canada blocks certain drug exports in response to US plan

Canada announced Saturday a ban on exporting certain medicines that are or may soon be in short supply, a measure in response to a US plan to import drugs from its northern neighbor. The plan promoted by outgoing US President Donald Trump aimed at allowing pharmacists and wholesalers to import certain prescription drugs in bulk from Canada takes effect on Monday. The US plan is intended to lower prices for Americans, but comes at a time when the Covid-19 pandemic has increased demand for some… Source link

Read More »

Combative U.S. FDA panel votes against Biogen Alzheimer's drug – Yahoo Finance

Bloomberg The Second Breakup of AT&T (Bloomberg) — AT&T Inc. has been called many things over its 135-year history: Ma Bell, monopoly, media conglomerate. The company, which traces its roots to the patent rights of telephone inventor Alexander Graham Bell, was the dominant phone company for much of the 20th century. So dominant, in fact, that it was broken up in 1982 as part of an agreement with antitrust authorities. But those businesses eventually began to merge, culminating with SBC… Source link

Read More »